Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
SANTA CLARA, Calif., June 01, 2017 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, announces depth and breadth of technologies that ignite and accelerate the development of new immune-oncology drug discovery.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/71dfadf0-8256-43cd-bafb-c429a8d37457
CrownBio scientific contribution to AACR:
- Technology which engrafts human immune cells into immunocompromised animals. When tested with immune activating agents, both short-term (PBMC) and long-term (CD34+ stem cell) engraftment strategies demonstrate robust anticancer activity.
- Syngeneic models - both in vitro and in vivo data utilizing their MuScreen™ platform, a large panel of well-characterized and validated syngeneic models, employed to test the activity of immune modulating anticancer drugs.
- Utilization of RNASeq data providing expression and mutation data from 18 cell lines. Investigators leverage this data to test both targeted therapy and immune-modulatory therapy in combination, thus providing rationale for clinical investigation.
- In vivo, the MuScreen platform enables an agnostic investigation of a compound’s activity and mechanism of action. MuScreen data can be followed-up with additional pharmacology studies, such as immunophenotyping, or bioluminescent assessment of metastatic burden.
“Our diligent focus on innovation, and continued scientific advancement charter unprecedented discovery in our immuno-oncology portfolio,” said Jean-Pierre Wery, CEO of CrownBio. “The robust contribution at this year’s annual meeting of the American Association for Cancer Research, on the part of our scientific team, validates an unwavering commitment to develop therapies that will impact the way cancer is treated.”
CrownBio can be located at ASCO Booth #17071. To schedule a meeting with our scientific leadership visit: https://www.crownbio.com/asco-meeting-req
For more information on CrownBio’s commitment to furthering the field of oncology and metabolic disease drug discovery, visit https://www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries: Jody Barbeau Crown Bioscience Inc. [email protected]
